CF
ENTA icon

Corebridge Financial’s Enanta Pharmaceuticals ENTA Stock Holding History

Corebridge Financial’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,841
Closed -$54.3K – 872
2025
Q1 		$54.3K Sell
9,841
-146
-1% -$902 ﹤0.01% 2706
2024
Q4 		$57.4K Sell
9,987
-754
-7% -$7.23K ﹤0.01% 2791
2024
Q3 		$111K Sell
10,741
-66
-0.6% -$863 ﹤0.01% 2566
2024
Q2 		$140K Buy
+10,807
New +$146K ﹤0.01% 2408

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corebridge Financial's ENTA Position: Q2 2025 in Review

Corebridge Financial sold out of Enanta Pharmaceuticals (ENTA) in Q2 2025, closing a stake of 9,841 shares — an estimated $54.3K sold.

Corebridge Financial first reported a position in ENTA in Q2 2024 and held it in 4 quarters. The position peaked at $140K in Q2 2024. 107 funds tracked by Wall St. Rank hold ENTA as of Q2 2025.

  • Corebridge Financial reported no remaining Enanta Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 9,841 Enanta Pharmaceuticals shares in Q2 2025, an estimated $54.3K.
  • Corebridge Financial first reported a position in Enanta Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Enanta Pharmaceuticals position peaked at $140K in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.